<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Progestogen hypersensitivity
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Progestogen hypersensitivity
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Progestogen hypersensitivity
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathleen M Buchheit, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan A Bernstein, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            N Franklin Adkinson, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna M Feldweg, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 22, 2020.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H856629869">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypersensitivity reactions to progestogens occur in women of reproductive age and can present with a heterogeneous group of cutaneous and/or systemic allergic reactions that correlate temporally with relative peaks in serum
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         levels. These reactions can be associated with endogenous or exogenous sources of progesterone. This topic will discuss the different types of reactions that have been attributed to progesterone hypersensitivity, what is known about pathogenesis, approaches to diagnosis, and interventions to alleviate symptoms.
        </p>
        <p class="headingAnchor" id="H1546099256">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          Progesterone
         </a>
         is a steroid hormone derived from cholesterol and is the main progestogen in the human body. The term "progestogen" refers to any natural or synthetic form of progesterone. The term "progestin" is specific for synthetic progestogens. Progestins are functionally similar but structurally different from natural progesterone.
        </p>
        <p>
         A variety of terms have been used in the medical literature to describe hypersensitivity reactions to progestogens, including "autoimmune
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         dermatitis," "progesterone allergy," and "progesterone hypersensitivity." The most commonly used term is "autoimmune progesterone dermatitis," which was introduced in 1964 [
         <a href="#rid1">
          1
         </a>
         ]. However, dermatitis is just one component in the range of reactions that have been reported, and progestogen hypersensitivity (PH) is not associated with other autoimmune diseases. Thus, the term "progestogen hypersensitivity" was subsequently proposed as a more accurate description of the multiple and varied reactions attributed to various forms of progesterone [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1011031665">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         PH predominantly affects women of reproductive age, with an average age of onset in the late 20s among cases described in the literature. There is a single reported case of hypersensitivity in a male patient receiving the progestin,
         <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">
          megestrol acetate
         </a>
         [
         <a href="#rid3">
          3
         </a>
         ]. PH appears to be rare, with fewer than 200 reported cases, although it may be under-recognized, and there are no published estimates of incidence or prevalence [
         <a href="#rid2">
          2,4
         </a>
         ]. PH has
         <strong>
          not
         </strong>
         been reported to develop in postmenopausal women treated with progestins as part of hormone replacement therapy (HRT).
        </p>
        <p class="headingAnchor" id="H726724885">
         <span class="h1">
          PROGESTERONE BIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          Progesterone
         </a>
         has multiple metabolic and physiologic effects related to the menstrual cycle, embryogenesis, pregnancy, and lactation [
         <a href="#rid5">
          5
         </a>
         ]. In addition to its role in reproduction, progesterone has anti-inflammatory properties and regulates T lymphocyte-mediated immune responses [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         In the normal menstrual cycle,
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         is released from the corpus luteum during the luteal phase and contributes to changes in the endometrium that prepare the uterus for implantation  (
         <a class="graphic graphic_figure graphicRef62189" href="/z/d/graphic/62189.html" rel="external">
          figure 1
         </a>
         ). Progesterone levels begin to rise 24 to 48 hours prior to ovulation and reach maximum levels on day 20 to 21 of a 28-day cycle [
         <a href="#rid6">
          6-8
         </a>
         ]. If pregnancy does not occur, progesterone levels decrease, resulting in menstruation. (See
         <a class="medical medical_review" href="/z/d/html/7418.html" rel="external">
          "Normal menstrual cycle"
         </a>
         .)
        </p>
        <p>
         If implantation occurs,
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         remains elevated and suppresses the maternal immune response to facilitate pregnancy [
         <a href="#rid5">
          5
         </a>
         ]. Increased progesterone during gestation may also contribute to relaxation of uterine smooth muscle contractility and inhibition of lactation. Decreasing progesterone levels are believed to precipitate labor and lactation.
        </p>
        <p class="headingAnchor" id="H3916949075">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptoms of PH include both cutaneous and noncutaneous signs and symptoms. Patients typically have either cutaneous or systemic symptoms, although the patient's reaction can evolve over time. In addition, a single patient may have more than one type of cutaneous reaction, such as erythema multiforme and urticaria [
         <a href="#rid9">
          9
         </a>
         ]. Signs and symptoms can vary somewhat from month to month.
        </p>
        <p class="headingAnchor" id="H1704591039">
         <span class="h2">
          Cutaneous manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cutaneous manifestations of PH may take several forms  (
         <a class="graphic graphic_picture graphicRef115694" href="/z/d/graphic/115694.html" rel="external">
          picture 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eczematous dermatitis [
         <a href="#rid10">
          10,11
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maculopapular rash [
         <a href="#rid12">
          12,13
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urticaria with or without angioedema [
         <a href="#rid14">
          14-19
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Papules and plaques [
         <a href="#rid12">
          12,13
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vesiculobullous and vesiculopustular lesions [
         <a href="#rid1">
          1,7,13
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Petechiae and purpura [
         <a href="#rid20">
          20,21
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fixed drug eruption  (
         <a class="graphic graphic_picture graphicRef116117" href="/z/d/graphic/116117.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid22">
          22,23
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vulvovaginal pruritus [
         <a href="#rid24">
          24
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stomatitis [
         <a href="#rid25">
          25,26
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Erythema multiforme [
         <a href="#rid27">
          27,28
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stevens-Johnson like syndrome (SJS) [
         <a href="#rid29">
          29,30
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         In each of the reports cited above, evidence for PH was provided through either positive
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         skin testing (ie, epicutaneous and intracutaneous with immediate reading, intracutaneous with delayed reading, or patch testing), a challenge with progesterone that elicited the implicated symptoms, or a clear response to treatment (such as suppression of ovulation or oophorectomy).
        </p>
        <p>
         Note that cutaneous PH is distinct from irritant reactions to injected
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         . Progesterone formulated for injection is suspended in various oils (commonly sesame or peanut), and patients can have local reactions to these injections. This would not be considered a form of PH. The irritant effects of the oils also need to be taken into account if skin testing is performed. (See
         <a class="local">
          'Skin testing'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1340283735">
         <span class="h2">
          Asthma or anaphylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         PH can also present with asthma or anaphylaxis, with or without other cutaneous manifestations [
         <a href="#rid2">
          2,17,22,31-34
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one detailed report, a 26-year-old woman was started on an estrogen-progestin oral contraceptive (OC) for management of oligomenorrhea and polycystic ovary syndrome and developed facial and lip angioedema, bronchospasm, and hypotension within two days [
         <a href="#rid33">
          33
         </a>
         ]. The OC was discontinued and restarted two weeks later, resulting in a similar reaction, followed by three additional episodes of anaphylaxis of increasing severity while she remained on the OC. Several years later, she developed a maculopapular dermatitis of her face and neck that appeared cyclically with her menstrual cycle.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 24 cases, 13 percent had asthma symptoms that were either perimenstrual or induced by an exogenous progestogen [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3899832172">
         <span class="h2">
          Onset of symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         In women exposed only to their endogenous
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         , PH can begin at any point after menarche, without a clear triggering event. In some patients, cyclical symptoms begin after completion of a normal pregnancy.
        </p>
        <p>
         For women exposed to exogenous progestogens, symptoms can begin any time after that exposure and can be elicited only by the exogenous source or by both the exogenous progestogen and by their normal cycles.
        </p>
        <p class="headingAnchor" id="H47575426">
         <span class="h2">
          Timing of symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptoms correlate temporally with progestogen exposure and differ with endogenous and exogenous progestogens.
        </p>
        <p class="headingAnchor" id="H1922987780">
         <span class="h3">
          In relation to the menstrual cycle
         </span>
         <span class="headingEndMark">
          —
         </span>
         For women reacting to endogenous
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         , the cyclical nature of the reactions relative to the menstrual cycle is a key diagnostic feature. Signs and symptoms appear during the peak progesterone levels of the luteal phase, most commonly 3 to 10 days before the onset of menses  (
         <a class="graphic graphic_figure graphicRef62189" href="/z/d/graphic/62189.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid2">
          2,4
         </a>
         ]. Symptoms usually resolve after the first few days of menstruation, although they can persist throughout the month. Patterns may be difficult to detect in women with irregular menses [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         The diagnosis of PH can be challenging to make in women with irregular cycles due to the difficulty in establishing correlations with
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         surges. Cycles longer than 45 days tend to be anovulatory or oligo-ovulatory. Other causes should be considered in these patients.
        </p>
        <p class="headingAnchor" id="H2636055663">
         <span class="h3">
          In relation to exogenous progestins
         </span>
         <span class="headingEndMark">
          —
         </span>
         In women being treated with exogenous progestins as part of contraception or fertility treatments, there may be no correlation to the underlying menstrual cycle, with symptoms corresponding instead to the administration of the exogenous progestogens.
        </p>
        <p class="headingAnchor" id="H4154302448">
         <span class="h3">
          During pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         During pregnancy, PH can begin intrapartum and may or may not resolve following childbirth
         <em>
         </em>
         [
         <a href="#rid35">
          35-37
         </a>
         ]. There are reports of patients with PH who developed worsening of symptoms during pregnancy as systemic
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         levels rose [
         <a href="#rid11">
          11,27
         </a>
         ]. Conversely, there are descriptions of patients with PH before pregnancy who improved in the intrapartum period [
         <a href="#rid17">
          17,38
         </a>
         ]. It has been proposed that improvement during pregnancy may be due to either autodesensitization to progesterone as levels gradually rise during pregnancy or an attenuation of maternal immune responses during pregnancy [
         <a href="#rid13">
          13
         </a>
         ]. PH has also been reported to begin during the postpartum period [
         <a href="#rid1">
          1,13,39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3673050615">
         <span class="h1">
          THEORIES OF PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The heterogeneity of clinical manifestations suggests that multiple mechanisms may be involved and that mechanisms may differ among patients.
        </p>
        <p class="headingAnchor" id="H2519256566">
         <span class="h2">
          Exposure to exogenous progestins or endogenous progesterone
         </span>
         <span class="headingEndMark">
          —
         </span>
         PH is usually reported in patients exposed to exogenous progestogens. Less commonly, the only known exposure has been the patient's own endogenous
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Common sources of exogenous progestins include oral contraceptive (OC) pills [
         <a href="#rid7">
          7,11,33
         </a>
         ], long-acting depot progestin preparations (eg,
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         [
         <a href="#rid16">
          16,38
         </a>
         ]), progestin-containing vaginal rings [
         <a href="#rid40">
          40
         </a>
         ], progestin-containing intrauterine devices (IUDs) [
         <a href="#rid2">
          2
         </a>
         ], and vaginal preparations used to support pregnancy [
         <a href="#rid41">
          41
         </a>
         ]. The high-dose
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         used during in vitro fertilization (IVF) is also associated with PH, and the resulting symptoms can limit the patient's ability to tolerate ongoing fertility treatment [
         <a href="#rid11">
          11
         </a>
         ]. In addition, there are reports of patients with symptoms following emergency contraception [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endogenous
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         is produced by the ovarian corpus luteum during the luteal phase of the menstrual cycle [
         <a href="#rid16">
          16,42
         </a>
         ]. During pregnancy, progesterone is produced by the corpus luteum and/or the placenta [
         <a href="#rid43">
          43,44
         </a>
         ]. (See
         <a class="local">
          'Timing of symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3515242364">
         <span class="h2">
          Proposed immunologic mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunologic drug reactions can be classified by mechanism  (
         <a class="graphic graphic_table graphicRef80466" href="/z/d/graphic/80466.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some presentations of PH may be type I, immediate hypersensitivity reactions  (
         <a class="graphic graphic_table graphicRef80466" href="/z/d/graphic/80466.html" rel="external">
          table 1
         </a>
         ). Classic mast cell-mediated symptoms include urticaria, angioedema, and anaphylaxis. In this model, progestogen-specific immunoglobulin E (IgE) antibodies are formed, usually following exposure to exogenous
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         or synthetic progestins used for contraception or hormonal supplementation. Most synthetic progestins are derived from adding or modifying the side chains of 19-nortestosterone, 17-alpha-hydroxyprogesterone, or 17-acetoxyprogesterone, so it is plausible that these compounds are sufficiently different from natural progesterone as to be recognized as foreign by the immune system. When subsequent exposure to a progestogen occurs, patients react due to cross-linking of these IgE antibodies on the surface of mast cell and/or basophils and activation of these cells. This mechanism is consistent with the observation that many cases of PH develop following exposure to the high doses of progesterone used in fertility treatments [
         <a href="#rid2">
          2,14,15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence that immediate hypersensitivity plays a role in some cases of PH is supported by the presence of positive skin testing results to
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         in some patients [
         <a href="#rid14">
          14,34
         </a>
         ]. (See
         <a class="local">
          'Skin testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence of basophil and mast cell activation using functional assays also supports an IgE-mediated immune response [
         <a href="#rid1">
          1,10,45
         </a>
         ]. In patients with immediate-type symptoms suggestive of PH but with negative skin prick testing to
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         , it has been proposed that progesterone may modulate mast cell and/or basophil reactivity, causing direct hormone-induced mast cell activation and release of bioactive mediators. However, studies evaluating the effect of estrogen and progesterone on basophil histamine release found that neither hormone influenced basophil histamine release. Mast cells have been shown to express receptors for both estradiol and progesterone [
         <a href="#rid46">
          46,47
         </a>
         ]. However, the effect of hormones on mast cells has not been studied directly [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some forms of PH may result from delayed, cell-mediated (type IV) reactions  (
         <a class="graphic graphic_table graphicRef80466" href="/z/d/graphic/80466.html" rel="external">
          table 1
         </a>
         ). Some cases were supported by delayed reactions to skin prick or intracutaneous testing with
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         [
         <a href="#rid35">
          35,43,49
         </a>
         ]. (See
         <a class="local">
          'Skin testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patch testing is a form of testing that can provide information about contact allergies. In a study of 19 patients with contact dermatitis to
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         , 5 of the 19 patients had positive patch testing to 17-alpha-progesterone. The authors posited that cross-sensitization to
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         resulted from primary sensitization to corticosteroids with similar structures. However, only two of the five patch test-positive patients in this study had symptoms consistent with PH [
         <a href="#rid50">
          50
         </a>
         ]. Furthermore, sensitivity to topical or oral corticosteroids does not seem to be a common finding among patients with PH, and these medications are sometimes used in the treatment of PH.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Severe reactions consistent with cyclical Stevens-Johnson like syndrome (SJS), which have been attributed to PH, are also considered a form of cell-mediated reaction [
         <a href="#rid29">
          29
         </a>
         ]. Testing is generally not performed for SJS like reactions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The formation of progesterone-specific immunoglobulin G (IgG) antibodies, with immune complex formation and tissue deposition (a type III immunologic reaction), has also been implicated in PH. In a case report, a patient with cyclical oral and perineal rashes was shown to have circulating IgG directed against 17-hydroxyprogesterone [
         <a href="#rid51">
          51
         </a>
         ]. However, the rate of asymptomatic IgG antibody formation in patients treated with
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         has not been studied. In another report, a patient with recurrent erythema multiforme during the luteal phase of the menstrual cycle had detectable cutaneous IgG immune complexes following challenge with medroxyprogesterone [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2117941977">
         <span class="h2">
          Possible risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epidemiologic studies to conclusively identify risk factors have not been performed, but clinical experience suggests that exposure to exogenous
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         , particularly in OCs or at high doses used in IVF, is a risk factor for the development of PH [
         <a href="#rid2">
          2,4,11,15
         </a>
         ]. One review of 89 cases found that 45 percent had known prior exposure to exogenous progestogen [
         <a href="#rid4">
          4
         </a>
         ]. However, exogenous progesterone exposure is not always present, and many patients experience symptoms only with endogenous progesterone exposure during menstruation or pregnancy [
         <a href="#rid20">
          20,52
         </a>
         ].
        </p>
        <p>
         PH is not believed to be a familial disorder, although there is one case report of three sisters with PH, which unfortunately did not provide details about each woman's
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         exposure [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3351964366">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation may involve some form of skin testing, depending upon the type of reaction. In addition, there may be situations in which a
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         challenge is helpful, although these are infrequent.
        </p>
        <p class="headingAnchor" id="H1092847">
         <span class="h2">
          Referral
         </span>
         <span class="headingEndMark">
          —
         </span>
         If PH is suspected but there is uncertainty about the diagnosis, the patient should be referred to an allergy specialist, if possible. Epicutaneous and intradermal skin testing are sometimes used in the evaluation of suspected immunoglobulin E (IgE)-mediated (type I) hypersensitivity. Skin testing for type I reactions should be performed by an allergist or clinician specifically trained in the safe performance and interpretation of this technique. (See
         <a class="medical medical_review" href="/z/d/html/5541.html" rel="external">
          "Overview of skin testing for IgE-mediated allergic disease"
         </a>
         .)
        </p>
        <p>
         We also recommend involving an allergist for patients presenting with any type of blistering skin reaction (eg, suspected Stevens-Johnson syndrome [SJS]) for further treatment recommendations. For patients with blistering reactions caused by exogenous progestogens, further exposure may be dangerous and should be avoided until the patient is evaluated further.
        </p>
        <p class="headingAnchor" id="H3869467011">
         <span class="h2">
          Patients with suspected IgE-mediated reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunoglobulin E (IgE)-mediated reactions involve signs and symptoms suggestive of mast cell-mediator release, such as pruritus, urticaria, angioedema, bronchospasm, hypotension, and/or anaphylaxis.
        </p>
        <p class="headingAnchor" id="H1455448517">
         <span class="h3">
          Skin testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin prick (also known as epicutaneous) and intracutaneous testing with
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         have been proposed as diagnostic tests to confirm suspected type I PH. However, there are several issues with validity, and not all allergy experts believe that skin testing is worthwhile [
         <a href="#rid2">
          2,14,19,53
         </a>
         ]. We suggest limiting the performance of progesterone skin testing to patients with symptoms suggestive of an IgE-mediated reaction that begins a few days before the onset of menses and resolves during or after the completion of menses.
        </p>
        <p>
         If performed, a positive skin testing result supports the diagnosis of PH in a patient with a compatible clinical history. However, the positive and negative predictive values of
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         skin testing are unknown. Therefore, a negative skin test result does not exclude the diagnosis, and there can be an irritant false-positive response. In addition, only a small number of asymptomatic, progesterone-exposed women have been skin tested as controls.
        </p>
        <p>
         A few studies provide information about the performance of
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         skin testing as a diagnostic test. Among patients with suggestive symptoms in one study, 50 percent had positive skin tests [
         <a href="#rid2">
          2
         </a>
         ]. In a review of cases reported in the literature, 64 of 67 cases had positive skin testing, but this would very likely represent a highly select population [
         <a href="#rid4">
          4
         </a>
         ]. One paper included a group of 12 control women in whom progesterone skin testing was performed to make sure that women without symptoms would not test positive, and all had negative results [
         <a href="#rid54">
          54
         </a>
         ]. In summary, data are very limited, and improved diagnostic tests are needed.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We use full concentration pharmaceutical grade
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         (50 mg/mL) for skin prick testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         At one author's (KB) center, a bio-identical
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         compounded with olive oil is used for skin testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If skin prick testing is negative, intradermal testing is performed next, with dilutions starting at a 0.05 mg/mL solution and increasing stepwise if negative with 0.5 and 5 mg/mL solutions [
         <a href="#rid2">
          2,15
         </a>
         ]. Higher concentrations can produce false-positive irritant responses.
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          Progesterone
         </a>
         is not soluble in water or
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         but can be suspended at the desired concentration in one of several oils (olive, sesame, peanut, or palm) or in ethanol.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Because these diluents can lead to false-positive irritant reactions in some patients, it is important to include the ethanol or oil diluent at the same concentration (but without
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         ) as a control, in addition to appropriate
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         (negative) and histamine (positive) controls [
         <a href="#rid2">
          2,55
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         A general discussion of skin testing techniques is found separately. (See
         <a class="medical medical_review" href="/z/d/html/5541.html" rel="external">
          "Overview of skin testing for IgE-mediated allergic disease", section on 'Skin testing methods'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H419757641">
         <span class="h3">
          Graded challenge
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          Progesterone
         </a>
         challenge has been used in the diagnosis of PH [
         <a href="#rid1">
          1,27
         </a>
         ]. Challenge could be considered in a patient with a negative or suspected irritant response to progesterone skin testing to confirm that the patient does not react. However, there are several issues that limit the safety or utility of progesterone challenge, such that it is usually not performed in clinical practice. Issues include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Challenge should not be performed in a patient with past anaphylaxis attributed to
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some patients with PH may not react to a single dose, so challenge may need to involve multiple doses.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some patients with PH can react with severe rashes that take weeks to resolve.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Depending on the clinical syndrome, a placebo-controlled challenge may be needed for definitive interpretation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with severe dermatitis as the manifestation of PH can react with an eruption that takes weeks to resolve.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2598814363">
         <span class="h3">
          In vitro testing (investigational)
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no commercially available in vitro tests for PH, although commercial assays are in development. Investigational in vitro assays that have been reported to be potentially useful in PH include direct leukocyte histamine release (LHR) assays performed on basophils and progesterone-specific IgE demonstrated by enzyme-linked immunosorbent assay (ELISA), although this is not commercially available [
         <a href="#rid33">
          33
         </a>
         ]. Interferon-gamma-release assay has also been proposed as a way to assess progesterone-related T cell activity [
         <a href="#rid39">
          39,56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2565204763">
         <span class="h2">
          Patients with other reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not advocate the use of delayed readings of intracutaneous tests or
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         patch testing for patients with possible PH, because the data are limited, and these techniques require further validation.
        </p>
        <p>
         We do not perform any type of testing or re-expose patients with erythema multiforme, SJS, or toxic epidermal necrolysis (TEN) to
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         , as even minor exposures can trigger a recurrence of symptoms.
        </p>
        <p class="headingAnchor" id="H2240744718">
         <span class="h2">
          Challenge with a GnRH agent
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gonadotropin-releasing hormone (GnRH) agonists, such as
         <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">
          leuprolide
         </a>
         acetate, can be given for two or three months as a diagnostic intervention if patients are accepting of the possible adverse effects. Alternatively, oral GnRH antagonists, such as
         <a class="drug drug_general" data-topicid="118522" href="/z/d/drug information/118522.html" rel="external">
          elagolix
         </a>
         and relugolix, which block the receptor, may also be options. Use of these agents should be supervised by a gynecologist or endocrinologist. Adverse effects are discussed below. (See
         <a class="local">
          'Women who have completed childbearing'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1406336750">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of PH is primarily based upon clinical history and physical examination. Confirmation of the presence of cutaneous or systemic symptoms that appear during the luteal phase of the menstrual cycle or symptoms that correlate with exposure to exogenous progestogens would be the minimal requirement for diagnosis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Depending on the symptom complex, positive immediate skin testing results support the diagnosis, but negative results do not conclusively exclude it, since other mechanisms may be involved. In addition, because the prevalence of positive skin testing to
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         among asymptomatic women has not been determined, a positive skin test, in the absence of suggestive symptoms is not sufficient to diagnose PH.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Resolution of symptoms with a gonadotropin-releasing hormone (GnRH) agonist challenge can also be considered diagnostic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other disorders that can mimic aspects of PH should be excluded. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1866172147">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential of PH affecting the skin includes dermatoses that fluctuate with the menstrual cycle. In patients with anaphylaxis, the differential includes other triggers of anaphylaxis that occur in association with menses or pregnancy, such as catamenial anaphylaxis or breastfeeding anaphylaxis [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1458767299">
         <span class="h2">
          NSAID hypersensitivity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonsteroidal anti-inflammatory drugs (NSAIDs), which are commonly used in the premenstrual period and the first few days of menses, can cause both urticaria/angioedema or systemic symptoms, including asthma and anaphylaxis [
         <a href="#rid40">
          40,58-60
         </a>
         ]. Patients can refrain from use of NSAIDs in order to determine if symptoms occur in their absence. Alternatively, an NSAID challenge could be performed to conclusively diagnose NSAID hypersensitivity. (See
         <a class="medical medical_review" href="/z/d/html/2082.html" rel="external">
          "NSAIDs (including aspirin): Allergic and pseudoallergic reactions"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2085.html" rel="external">
          "Diagnostic challenge and desensitization protocols for NSAID reactions"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H597675517">
         <span class="h2">
          Chronic idiopathic urticaria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic idiopathic (or spontaneous) urticaria (CIU) is defined as the presence of urticaria with or without angioedema on most days of the week for a period of six weeks or longer. Patients with CIU would be expected to have symptoms outside of the luteal phase of the menstrual cycle, although symptoms might worsen perimenstrually or with NSAID use.
        </p>
        <p class="headingAnchor" id="H4103119747">
         <span class="h2">
          Premenstrual exacerbation of a pre-existing dermatosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients may have pre-existing atopic dermatitis, contact dermatitis, acne, psoriasis, or any number of other skin conditions that worsen in temporal relation to menses [
         <a href="#rid61">
          61,62
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2326930674">
         <span class="h2">
          Estrogen hypersensitivity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypersensitivity to endogenous and exogenous estrogens has also been described and appears to be even rarer than PH [
         <a href="#rid63">
          63-67
         </a>
         ]. Estrogen hypersensitivity characteristically presents as a premenstrual flare of urticaria or a delayed-type dermatitis [
         <a href="#rid63">
          63
         </a>
         ]. However, estrogen levels peak earlier in the menstrual cycle (ie, days 6 to 14), compared with
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         , although there is a secondary rise during the luteal phase that mirrors the rise in progesterone. The diagnosis is supported by a positive immediate or delayed intracutaneous estrogen test [
         <a href="#rid63">
          63,64
         </a>
         ] or an estrogen challenge [
         <a href="#rid65">
          65
         </a>
         ]. Treatments for patients reacting to endogenous estrogens are similar to those for PH and include suppression of estrogen with
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         ,
         <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">
          leuprolide
         </a>
         acetate, progestin-only contraceptives, or oophorectomy [
         <a href="#rid63">
          63-67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H294104971">
         <span class="h2">
          Catamenial dermatoses and anaphylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         "Catamenial" (of or relating to menstruation) dermatoses and anaphylaxis are also temporally associated with the menstrual cycle, but symptoms correlate with the onset of menses, whereas PH correlates with the period of peak
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         concentrations prior to the onset of menses [
         <a href="#rid31">
          31
         </a>
         ]. However, the term "catamenial anaphylaxis" has been used loosely in the literature and has been applied to premenstrual reactions to progesterone [
         <a href="#rid68">
          68,69
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          Progesterone
         </a>
         and estrogen both decline significantly prior to the onset of menses  (
         <a class="graphic graphic_figure graphicRef62189" href="/z/d/graphic/62189.html" rel="external">
          figure 1
         </a>
         ). It has been proposed that symptoms beginning with the onset of menses are triggered by endometrial release of prostaglandins, which peak on the first day of menses [
         <a href="#rid70">
          70,71
         </a>
         ]. The endometrium synthesizes prostaglandin F
         <sub>
          2
         </sub>
         (PGF
         <sub>
          2
         </sub>
         ) [
         <a href="#rid72">
          72
         </a>
         ] and has been implicated in mediator release by uterine mast cells [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
         In a case report of recurrent anaphylaxis occurring in the first 24 hours of menses,
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         , which inhibits prostaglandins, was beneficial. Complete resolution of the patient's symptoms occurred following hysterectomy and salpingo-oophorectomy [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1185950904">
         <span class="h2">
          Breastfeeding anaphylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are rare case reports of anaphylaxis associated with breastfeeding [
         <a href="#rid58">
          58-60,74
         </a>
         ]. Symptoms most commonly begin in the first few days after delivery and are associated with the act of breastfeeding or the manual expression of breast milk. Elevations in serum tryptase have been documented [
         <a href="#rid60">
          60
         </a>
         ]. The pathophysiology of lactation-associated anaphylaxis is not well-understood, but one theory is that a rapid decrease in
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         leads to an exaggerated histamine response [
         <a href="#rid60">
          60
         </a>
         ]. Hypersensitivity to prolactin and oxytocin has also been explored, but skin testing to these hormones was negative [
         <a href="#rid59">
          59,60
         </a>
         ]. In some patients, the symptoms resolve after several days of breastfeeding, although they may occur with subsequent pregnancies [
         <a href="#rid59">
          59,74
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/393.html" rel="external">
          "Anaphylaxis during pregnancy and delivery"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2110623518">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment for PH varies widely based on symptoms and preferences regarding fertility but generally focuses on controlling specific symptoms or inducing anovulation in women who do not wish to conceive in the near future
         <em>
          .
         </em>
         Coordination between the allergist/immunologist or dermatologist and the gynecologist and/or reproductive endocrinologist may be needed, depending upon the individual patient's goals.
        </p>
        <p class="headingAnchor" id="H3622248296">
         <span class="h2">
          Antiallergy medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The simplest approach to management of PH is avoidance (if exogenous progestogens are the cause of the symptoms) and/or suppression of symptoms if
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         is endogenous or necessary. Antihistamines are used to treat pruritus, urticaria, and angioedema, with variable reports of success [
         <a href="#rid9">
          9,17,32,75
         </a>
         ]. A step-wise approach to management, similar to that used for chronic idiopathic (spontaneous) urticaria, is appropriate [
         <a href="#rid76">
          76
         </a>
         ]. Second-generation H1 antihistamines, such as
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9443" href="/z/d/drug information/9443.html" rel="external">
          levocetirizine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">
          loratadine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8472" href="/z/d/drug information/8472.html" rel="external">
          desloratadine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8445" href="/z/d/drug information/8445.html" rel="external">
          fexofenadine
         </a>
         , are minimally sedating and preferred over first-generation agents, such as
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         and
         <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">
          hydroxyzine
         </a>
         . Some patients require higher than standard doses for control of symptoms. Use of H1 antihistamines at higher than standard doses is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8106.html" rel="external">
          "Chronic spontaneous urticaria: Standard management and patient education", section on 'H1 antihistamines'
         </a>
         .)
        </p>
        <p>
         Topical and oral glucocorticoids have both shown to have efficacy in some studies [
         <a href="#rid11">
          11,51
         </a>
         ], although they are not a viable long-term option for many patients due to the potential for adverse systemic side effects.
        </p>
        <p class="headingAnchor" id="H3962520564">
         <span class="h2">
          Oral contraceptive with a constant progesterone dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         A simple early intervention that is variably successful is treatment with an oral contraceptive (OC) that contains a constant
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         dose, which should be administered continuously. This would not be appropriate in patients with anaphylaxis or blistering of the skin or mucous membranes, as these patients should not be purposefully exposed to exogenous progestogens. (See
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Dosing regimens'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H443047254">
         <span class="h2">
          Progesterone desensitization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Various types of desensitization protocols
         <strong>
         </strong>
         have been used to alleviate symptoms of
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         hypersensitivity in small numbers of patients [
         <a href="#rid2">
          2,15,17
         </a>
         ]. The exact mechanisms underlying desensitization are incompletely understood. Desensitization does not "cure" a drug hypersensitivity but rather is a means of preventing symptoms for as long as the patient remains continually exposed to the drug. Therefore, it is appropriate for patients who will either remain on continual progesterone (eg, OCs) or for those who require exposure for a limited period of time (eg, during fertility treatments).
        </p>
        <p class="headingAnchor" id="H2902699033">
         <span class="h3">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Indications for desensitization include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with nonanaphylactic symptoms who have failed initiation of an OCP without desensitization. (See
         <a class="local">
          'Oral contraceptive with a constant progesterone dose'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         And
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe symptoms not controlled with standard medications, such as antihistamines or glucocorticoids, or the desire to avoid long-term use of these medications [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         And/or
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The need for high-dose
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         for in vitro fertilization (IVF) [
         <a href="#rid15">
          15,17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/134342.html" rel="external">
          "In vitro fertilization: Procedure", section on 'Luteal phase support'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H330879205">
         <span class="h3">
          Safety
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with urticaria, asthma, or anaphylaxis to
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         , desensitization protocols should be performed by allergists or clinicians with specific training in allergy procedures. Because these symptoms are indicative of a possible immunoglobulin E (IgE)-mediated mechanism, patients should be desensitized in a setting equipped with the staff and medications necessary to manage anaphylaxis. Successful completion of a desensitization protocol may require temporarily suspending the procedure if symptoms develop, treatment, and adjustments to the subsequent steps, all of which require some experience in desensitization techniques.
        </p>
        <p>
         For patients with mild, nonurticarial cutaneous reactions, desensitization has been found to be well-tolerated and carry little risk, although experience with desensitization techniques is recommended.
        </p>
        <p class="headingAnchor" id="H2057200008">
         <span class="h3">
          Specific protocols
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid drug desensitization protocols are appropriate for immediate reactions (eg, urticaria, angioedema, asthma, and/or anaphylaxis) [
         <a href="#rid77">
          77-79
         </a>
         ]. These protocols typically take a few hours to complete. Examples are provided  (
         <a class="graphic graphic_table graphicRef116121" href="/z/d/graphic/116121.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef116118" href="/z/d/graphic/116118.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef115603" href="/z/d/graphic/115603.html" rel="external">
          table 4
         </a>
         ), each of which has been successfully applied to three or fewer patients whose skin test sensitivities were not specified. A detailed discussion of rapid drug desensitization for immediate-type reactions is found separately. (See
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There are also gradual dose escalation protocols that are typically applied to delayed forms of drug reactions in the absence of positive skin tests, which includes most of the cutaneous forms of PH (eg, various forms of dermatitis). These protocols usually take a few days to complete. An OC containing both estrogen and progestin is usually preferred. An example is provided  (
         <a class="graphic graphic_table graphicRef115602" href="/z/d/graphic/115602.html" rel="external">
          table 5
         </a>
         ). This protocol was successful in six of seven patients in which it was employed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We have also seen patients in whom OCs were initiated without a desensitization protocol and continued without interruption with good results. However, this is not consistently effective.
        </p>
        <p>
        </p>
        <p>
         We typically administer
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         (50 mg orally) and
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (40 mg orally for three days) as premedications prior to desensitizations that take place over a few hours
         <em>
          .
         </em>
         During the procedure, if patients develop symptoms, we sometimes adjust the protocol by backing up to the last tolerated dose and progressing more gradually through the steps that elicited symptoms.
        </p>
        <p class="headingAnchor" id="H3931754370">
         <span class="h2">
          Omalizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         , a monoclonal antibody to IgE, has been used successfully in a young woman with urticaria and anaphylaxis due to PH [
         <a href="#rid34">
          34
         </a>
         ]. Omalizumab is well-tolerated and has few adverse effects, although it is effective only as long as it is administered. (See
         <a class="medical medical_review" href="/z/d/html/545.html" rel="external">
          "Anti-IgE therapy"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         can also be administered to facilitate desensitization. For patients who failed an initial attempt at desensitization due to breakthrough symptoms during the procedure, a dose of omalizumab can also be given prior to a second attempt at desensitization.
        </p>
        <p class="headingAnchor" id="H902560261">
         <span class="h2">
          Therapies with significant limitations
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several other therapies for PH that have either significant adverse effects or permanently impair fertility, such that they have limited utility. These include gonadotropin-releasing hormone (GnRH) agonists,
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         , and oophorectomy. (See
         <a class="local">
          'Women who have completed childbearing'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2875343565">
         <span class="h2">
          Approach for different patient groups
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal approach to management depends upon whether the patient is hoping only to relieve symptoms, is also undergoing fertility therapies, or has completed childbearing.
        </p>
        <p class="headingAnchor" id="H1658104383">
         <span class="h3">
          Women not desiring pregnancy in the near future
         </span>
         <span class="headingEndMark">
          —
         </span>
         OCs that contain both estrogen and progestins can eliminate the
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         peaks that trigger symptoms. However, if just initiated normally, OCs may not be well-tolerated by all patients with PH [
         <a href="#rid38">
          38
         </a>
         ].
         <em>
         </em>
         In patients who do not tolerate OCs initiated normally, OCs can be introduced using a slow oral protocol  (
         <a class="graphic graphic_table graphicRef115602" href="/z/d/graphic/115602.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid2">
          2,12
         </a>
         ]. Preparations containing estrogen combined with a constant dose of progestin throughout the cycle are usually chosen, and these are given continuously without stopping to allow for menstruation, as this could permit resensitization. The steady level of progesterone usually results in improvement in symptoms. (See
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Dosing regimens'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3459821882">
         <span class="h3">
          Women wishing to conceive
         </span>
         <span class="headingEndMark">
          —
         </span>
         For women with PH who wish to conceive, options include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Manage symptoms with antihistamines and glucocorticoids and conceive naturally with the hope that autodesensitization will occur as a result of pregnancy. There are no data to suggest that PH directly causes infertility.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initiate
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         (anti-IgE therapy). This would be appropriate for PH presenting as urticaria, asthma, or anaphylaxis and is considered safe to continue during pregnancy (if needed) [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1017885418">
         <span class="h3">
          Women undergoing fertility treatments
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women undergoing fertility treatments who have developed PH usually need to be desensitized to tolerate the high doses of
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         required for successful implantation. There are several reports of rapid-dose escalation ("desensitization") to high-dose progesterone that was required for IVF [
         <a href="#rid15">
          15,17
         </a>
         ]. Varied protocols that require several hours to complete have been designed using oral, intravaginal, or intramuscular progesterone [
         <a href="#rid2">
          2,14,15
         </a>
         ]. Desensitization is timed to coordinate with fertility treatment, such as immediately prior to embryo transfer  (
         <a class="graphic graphic_table graphicRef116118" href="/z/d/graphic/116118.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef115603" href="/z/d/graphic/115603.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid2">
          2,12,15
         </a>
         ]. Close coordination with the fertility specialist is essential. It is noteworthy that some of the reported cases of "desensitization" included premedication with steroids and other drugs, and no patients have been re-skin tested after tolerance to demonstrate cellular desensitization, so the mechanism underlying this clinical tolerance is not proven.
        </p>
        <p class="headingAnchor" id="H24533078">
         <span class="h3">
          Women who have completed childbearing
         </span>
         <span class="headingEndMark">
          —
         </span>
         For women who have completed childbearing, treatment options include rapid-dose escalation ("desensitization") to and continuous use of an estrogen- and progesterone-containing OC until menopause. Alternatively, there are other options with significant drawbacks, including GnRH agonists,
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         , and oophorectomy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         GnRH agonists, such as
         <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">
          leuprolide
         </a>
         acetate, have been used to treat PH in patients with severe symptoms refractory to other medical therapies [
         <a href="#rid16">
          16,32,33,38,80,81
         </a>
         ]. At doses used to suppress ovulation, GnRH agonists inhibit pituitary gonadotropin release, thus inhibiting ovulation and suppressing luteal
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         [
         <a href="#rid82">
          82
         </a>
         ]. In a double-blind crossover study in four women with history of recurrent anaphylaxis corresponding to the luteal phase, all received either GnRH agonists or placebo [
         <a href="#rid81">
          81
         </a>
         ]. Two of the four patients improved on the GnRH agonist, while the other two had no response. The two who improved had positive skin tests to
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         and anaphylaxis to intravenous challenge with luteinizing hormone-releasing hormone, consistent with PH [
         <a href="#rid81">
          81
         </a>
         ]. One of the authors (JB) has successfully used an intranasal GnRH agonist (
         <a class="drug drug_general" data-topicid="9673" href="/z/d/drug information/9673.html" rel="external">
          nafarelin
         </a>
         ) to control symptoms (unpublished). GnRH agonists have significant adverse effects, including hot flashes, amenorrhea, urogenital atrophy, and bone loss [
         <a href="#rid83">
          83-85
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7416.html" rel="external">
          "Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists", section on 'Side effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          Tamoxifen
         </a>
         is a selective estrogen receptor modulator that has been reported to be useful in treating PH, although the authors have not used it in their own practices [
         <a href="#rid26">
          26,27,42
         </a>
         ]. In premenopausal women, tamoxifen induces ovulation, but if given daily over time, women can become oligo- or amenorrheic. Adverse effects include hot flashes, increased risk of thromboembolic events, abnormal uterine bleeding, and other uterine pathology. (See
         <a class="medical medical_review" href="/z/d/html/14204.html" rel="external">
          "Abnormal uterine bleeding and uterine pathology in patients on tamoxifen therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oophorectomy has been employed as a definitive treatment for patients with severe PH that cannot otherwise be managed medically [
         <a href="#rid1">
          1,25,30,52,86
         </a>
         ]. A trial of a GnRH agonist beforehand would be helpful to confirm that symptoms improve when endogenous
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         is suppressed.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2056739696">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         We have not observed spontaneous resolution of PH in the absence of either some therapeutic intervention or natural menopause. Patients respond in varying degrees to the interventions described above, but in most cases, symptoms can be managed to the patient's satisfaction.
        </p>
        <p class="headingAnchor" id="H984050019">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Progestogen hypersensitivity (PH) is a form of cyclic hypersensitivity that may be more common than reported that can develop in women of reproductive age beginning any time from menarche to menopause, although it is more common in younger women. It can present with a spectrum of cutaneous and/or systemic allergic signs and symptoms, correlating temporally with relative peaks in serum
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         levels. (See
         <a class="local">
          'Terminology'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the normal menstrual cycle,
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         is released from the corpus luteum during the luteal phase (ie, days 14 to 28 of a 28-day cycle)  (
         <a class="graphic graphic_figure graphicRef62189" href="/z/d/graphic/62189.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Progesterone biology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PH may present with a broad array of cutaneous and systemic signs and symptoms. Most patients either have cutaneous presentations (dermatitis, urticaria, papular or vesicular eruptions) or asthma/anaphylaxis. For women reacting to endogenous
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         , the cyclical nature of the reactions relative to the menstrual cycle is a key diagnostic clue. Symptoms typically begin 3 to 10 days before the onset of menses and resolve after the first few days of menstruation. For women reacting to exogenous progestogens, the symptoms follow exposure. During pregnancy, PH can begin intrapartum and may or may not resolve following childbirth. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The heterogeneity of clinical presentations suggests that multiple mechanisms may be involved and that mechanisms may differ among patients. Types I, III, and IV reactions have all been implicated  (
         <a class="graphic graphic_table graphicRef80466" href="/z/d/graphic/80466.html" rel="external">
          table 1
         </a>
         ). Women may have a history of exposure to exogenous progestogens, particularly during fertility treatment, but some patients have no such history, and risk factors have not been identified. (See
         <a class="local">
          'Theories of pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation includes progesterone-specific IgE testing. Skin testing to
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         is unreliable and can result in false positive or negative results, so we perform it rarely and usually for cases of immediate-type allergic symptoms. Progesterone challenge has also been used but is infrequently performed. Suppression of the menstrual cycle with a gonadotropin-releasing hormone (GnRH) agonist resulting in resolution of symptoms is also diagnostic. The minimal criteria for diagnosis of PH are suggestive signs and symptoms that appear during the luteal phase of the menstrual cycle or symptoms that correlate with exposure to exogenous progestogens. (See
         <a class="local">
          'Evaluation'
         </a>
         above and
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The differential diagnosis includes other causes of cyclic hypersensitivity, reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) taken in the perimenstrual period, chronic idiopathic (or spontaneous) urticaria (CIU), premenstrual exacerbations of other skin disorders, and several other rare conditions. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management options include suppression of symptoms with antiallergy medications,
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         desensitization,
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         , therapies to suppress ovulation (eg,
         <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">
          leuprolide
         </a>
         acetate), use of a selective estrogen receptor modulator like
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         , and oophorectomy. Different approaches are used for women wishing to suppress symptoms but preserve future fertility, those actively undergoing fertility treatments, and those who have completed childbearing. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           SHELLEY WB, PREUCEL RW, SPOONT SS. AUTOIMMUNE PROGESTERONE DERMATITIS. CURE BY OOPHORECTOMY. JAMA 1964; 190:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foer D, Buchheit KM, Gargiulo AR, et al. Progestogen Hypersensitivity in 24 Cases: Diagnosis, Management, and Proposed Renaming and Classification. J Allergy Clin Immunol Pract 2016; 4:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher DA. Drug-induced progesterone dermatitis. J Am Acad Dermatol 1996; 34:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen T, Razzaque Ahmed A. Autoimmune progesterone dermatitis: Update and insights. Autoimmun Rev 2016; 15:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taraborrelli S. Physiology, production and action of progesterone. Acta Obstet Gynecol Scand 2015; 94 Suppl 161:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           FORBES TR. Systemic plasma progesterone levels during the human menstrual cycle. Am J Obstet Gynecol 1950; 60:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hart R. Autoimmune progesterone dermatitis. Arch Dermatol 1977; 113:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stocco C, Telleria C, Gibori G. The molecular control of corpus luteum formation, function, and regression. Endocr Rev 2007; 28:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walling HW, Scupham RK. Autoimmune progesterone dermatitis. Case report with histologic overlap of erythema multiforme and urticaria. Int J Dermatol 2008; 47:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones WN, Gordon VH. Auto-immune progesterone eczema. An endogenous progesterone hypersensitivity. Arch Dermatol 1969; 99:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenkins J, Geng A, Robinson-Bostom L. Autoimmune progesterone dermatitis associated with infertility treatment. J Am Acad Dermatol 2008; 58:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchheit KM, Bernstein JA. Progestogen Hypersensitivity: Heterogeneous Manifestations with a Common Trigger. J Allergy Clin Immunol Pract 2017; 5:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herzberg AJ, Strohmeyer CR, Cirillo-Hyland VA. Autoimmune progesterone dermatitis. J Am Acad Dermatol 1995; 32:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill JL, Carr TF. Iatrogenic autoimmune progesterone dermatitis treated with a novel intramuscular progesterone desensitization protocol. J Allergy Clin Immunol Pract 2013; 1:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prieto-Garcia A, Sloane DE, Gargiulo AR, et al. Autoimmune progesterone dermatitis: clinical presentation and management with progesterone desensitization for successful in vitro fertilization. Fertil Steril 2011; 95:1121.e9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baptist AP, Baldwin JL. Autoimmune progesterone dermatitis in a patient with endometriosis: case report and review of the literature. Clin Mol Allergy 2004; 2:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poole JA, Rosenwasser LJ. Chronic idiopathic urticaria exacerbated with progesterone therapy treated with novel desensitization protocol. J Allergy Clin Immunol 2004; 114:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farah FS, Shbaklu Z. Autoimmune progesterone urticaria. J Allergy Clin Immunol 1971; 48:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vasconcelos C, Xavier P, Vieira AP, et al. Autoimmune progesterone urticaria. Gynecol Endocrinol 2000; 14:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wintzen M, Goor-van Egmond MB, Noz KC. Autoimmune progesterone dermatitis presenting with purpura and petechiae. Clin Exp Dermatol 2004; 29:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mbonile L. Autoimmune progesterone dermatitis: Case report with history of urticaria, petechiae and palpable pinpoint purpura triggered by medical abortion. S Afr Med J 2016; 106:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Honda T, Kabashima K, Fujii Y, et al. Autoimmune progesterone dermatitis that changed its clinical manifestation from anaphylaxis to fixed drug eruption-like erythema. J Dermatol 2014; 41:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asai J, Katoh N, Nakano M, et al. Case of autoimmune progesterone dermatitis presenting as fixed drug eruption. J Dermatol 2009; 36:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banerjee AK, de Chazal R. Chronic vulvovaginal pruritus treated successfully with GnRH analogue. Postgrad Med J 2006; 82:e22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger H. Progesterone. Arch Dermatol 1969; 100:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moghadam BK, Hersini S, Barker BF. Autoimmune progesterone dermatitis and stomatitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wojnarowska F, Greaves MW, Peachey RD, et al. Progesterone-induced erythema multiforme. J R Soc Med 1985; 78:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maguire T. Autoimmune progesterone dermatitis. Dermatol Nurs 2009; 21:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drayer SM, Laufer LR, Farrell ME. Autoimmune Progesterone Dermatitis Presenting as Stevens-Johnson Syndrome. Obstet Gynecol 2017; 130:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drayer SM, Laufer LR, Farrell ME. Autoimmune Progesterone Dermatitis Mistaken for Stevens-Johnson Syndrome. Obstet Gynecol 2018; 131:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snyder JL, Krishnaswamy G. Autoimmune progesterone dermatitis and its manifestation as anaphylaxis: a case report and literature review. Ann Allergy Asthma Immunol 2003; 90:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meggs WJ, Pescovitz OH, Metcalfe D, et al. Progesterone sensitivity as a cause of recurrent anaphylaxis. N Engl J Med 1984; 311:1236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein IL, Bernstein DI, Lummus ZL, Bernstein JA. A case of progesterone-induced anaphylaxis, cyclic urticaria/angioedema, and autoimmune dermatitis. J Womens Health (Larchmt) 2011; 20:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heffler E, Fichera S, Nicolosi G, Crimi N. Anaphylaxis due to progesterone hypersensitivity successfully treated with omalizumab. J Allergy Clin Immunol Pract 2017; 5:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teelucksingh S, Edwards CR. Autoimmune progesterone dermatitis. J Intern Med 1990; 227:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brestel EP, Thrush LB. The treatment of glucocorticosteroid-dependent chronic urticaria with stanozolol. J Allergy Clin Immunol 1988; 82:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medeiros S, Rodrigues-Alves R, Costa M, et al. Autoimmune progesterone dermatitis: treatment with oophorectomy. Clin Exp Dermatol 2010; 35:e12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toms-Whittle LM, John LH, Griffiths DJ, Buckley DA. Autoimmune progesterone dermatitis: a diagnosis easily missed. Clin Exp Dermatol 2011; 36:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halevy S, Cohen AD, Lunenfeld E, Grossman N. Autoimmune progesterone dermatitis manifested as erythema annulare centrifugum: Confirmation of progesterone sensitivity by in vitro interferon-gamma release. J Am Acad Dermatol 2002; 47:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camões S, Sampaio J, Rocha J, et al. Autoimmune progesterone dermatitis: Case report of an unexpected treatment reaction. Australas J Dermatol 2017; 58:e132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanninen TT, Moretti ML, Lakhi NA. Autoimmune progesterone dermatitis following vaginal progesterone exposure in pregnancy. Obstet Med 2019; 12:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cocuroccia B, Gisondi P, Gubinelli E, Girolomoni G. Autoimmune progesterone dermatitis. Gynecol Endocrinol 2006; 22:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Georgouras K. Autoimmune progesterone dermatitis. Australas J Dermatol 1981; 22:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bierman SM. Autoimmune progesterone dermatitis of pregnancy. Arch Dermatol 1973; 107:896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miura T, Matsuda M, Yanbe H, Sugiyama S. Two cases of autoimmune progesterone dermatitis. Immunohistochemical and serological studies. Acta Derm Venereol 1989; 69:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zierau O, Zenclussen AC, Jensen F. Role of female sex hormones, estradiol and progesterone, in mast cell behavior. Front Immunol 2012; 3:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaitsu M, Narita S, Lambert KC, et al. Estradiol activates mast cells via a non-genomic estrogen receptor-alpha and calcium influx. Mol Immunol 2007; 44:1977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slater JE, Kaliner M. Effects of sex hormones on basophil histamine release in recurrent idiopathic anaphylaxis. J Allergy Clin Immunol 1987; 80:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chawla SV, Quirk C, Sondheimer SJ, James WD. Autoimmune progesterone dermatitis. Arch Dermatol 2009; 145:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoenmakers A, Vermorken A, Degreef H, Dooms-Goossens A. Corticosteroid or steroid allergy? Contact Dermatitis 1992; 26:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheesman KL, Gaynor LV, Chatterton RT Jr, Radvany RM. Identification of a 17-hydroxyprogesterone-binding immunoglobulin in the serum of a woman with periodic rashes. J Clin Endocrinol Metab 1982; 55:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moody BR, Schatten S. Autoimmune progesterone dermatitis: onset in a women without previous exogenous progesterone exposure. South Med J 1997; 90:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-Ortega P, Scorza E. Progesterone autoimmune dermatitis with positive autologous serum skin test result. Obstet Gynecol 2011; 117:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellaithy MI, Fathi HM, Farres MN, Taha MS. Skin test reactivity to female sex hormones in women with primary unexplained recurrent pregnancy loss. J Reprod Immunol 2013; 99:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BAER RL, WITTEN VH, ALLEN JR. Skin tests with endocrine substances; method of Zondek and Bromberg. Ann Allergy 1948; 6:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghosh D, Bernstein JA. Development of a progesterone-specific IgE assay for diagnosing patients with suspected progestogen hypersensitivity. Ann Allergy Asthma Immunol 2019; 122:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavery WJ, Bernstein JA. Cyclical hypersensitivity, anaphylaxis, and related hormonal reaction. Ann Allergy Asthma Immunol 2019; 122:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKinney KK, Scranton SE. A case report of breastfeeding anaphylaxis: successful prophylaxis with oral antihistamines. Allergy 2011; 66:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shank JJ, Olney SC, Lin FL, McNamara MF. Recurrent postpartum anaphylaxis with breast-feeding. Obstet Gynecol 2009; 114:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mullins RJ, Russell A, McGrath GJ, et al. Breastfeeding anaphylaxis. Lancet 1991; 338:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghunath RS, Venables ZC, Millington GW. The menstrual cycle and the skin. Clin Exp Dermatol 2015; 40:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zachary C, Fackler N, Juhasz M, et al. Catamenial dermatoses associated with autoimmune, inflammatory, and systemic diseases: A systematic review,. Int J Womens Dermatol 2019; 5:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shelley WB, Shelley ED, Talanin NY, Santoso-Pham J. Estrogen dermatitis. J Am Acad Dermatol 1995; 32:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leylek OA, Unlü S, Oztürkcan S, et al. Estrogen dermatitis. Eur J Obstet Gynecol Reprod Biol 1997; 72:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayou SC, Charles-Holmes R, Kenney A, Black MM. A premenstrual urticarial eruption treated with bilateral oophorectomy and hysterectomy. Clin Exp Dermatol 1988; 13:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Randall K, Steele R. Estrogen dermatitis: treatment with progestin-only pill. Arch Dermatol 2005; 141:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon TY, Kim YG, Kim MK. Estrogen dermatitis responding to leuprolide acetate. J Dermatol 2005; 32:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer CS, Kampitak T, Messieh ML, et al. Heterogeneity in presentation and treatment of catamenial anaphylaxis. Ann Allergy Asthma Immunol 2013; 111:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberman P. Catamenial anaphylaxis. J Allergy Clin Immunol Pract 2014; 2:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burstein M, Rubinow A, Shalit M. Cyclic anaphylaxis associated with menstruation. Ann Allergy 1991; 66:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verdolini R, Atkar R, Clayton N, et al. Catamenial dermatoses: has anyone ever considered prostaglandins? Clin Exp Dermatol 2014; 39:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh EJ, Baccarini I, Zuspan FP. Levels of prostaglandins F-2alpha and E-2 in human endometrium during the menstrual cycle. Am J Obstet Gynecol 1975; 121:1003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudolph MI, Reinicke K, Cruz MA, et al. Distribution of mast cells and the effect of their mediators on contractility in human myometrium. Br J Obstet Gynaecol 1993; 100:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villalta D, Martelli P. A case of breastfeeding anaphylaxis. Eur Ann Allergy Clin Immunol 2007; 39:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shahar E, Bergman R, Pollack S. Autoimmune progesterone dermatitis: effective prophylactic treatment with danazol. Int J Dermatol 1997; 36:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014; 133:1270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brennan PJ, Rodriguez Bouza T, Hsu FI, et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009; 124:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sloane D, Govindarajulu U, Harrow-Mortelliti J, et al. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract 2016; 4:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yee KC, Cunliffe WJ. Progesterone-induced urticaria: response to buserelin. Br J Dermatol 1994; 130:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slater JE, Raphael G, Cutler GB Jr, et al. Recurrent anaphylaxis in menstruating women: treatment with a luteinizing hormone-releasing hormone agonist--a preliminary report. Obstet Gynecol 1987; 70:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortmann O, Weiss JM, Diedrich K. Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action. Reprod Biomed Online 2002; 5 Suppl 1:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Surrey ES. Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group. Fertil Steril 1999; 71:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol 1998; 91:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol 2002; 99:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ródenas JM, Herranz MT, Tercedor J. Autoimmune progesterone dermatitis: treatment with oophorectomy. Br J Dermatol 1998; 139:508.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13539 Version 10.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14197141" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : AUTOIMMUNE PROGESTERONE DERMATITIS. CURE BY OOPHORECTOMY.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27090357" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Progestogen Hypersensitivity in 24 Cases: Diagnosis, Management, and Proposed Renaming and Classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8632095" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Drug-induced progesterone dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26554933" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Autoimmune progesterone dermatitis: Update and insights.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26358238" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Physiology, production and action of progesterone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15425576" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Systemic plasma progesterone levels during the human menstrual cycle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/192155" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Autoimmune progesterone dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17077191" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The molecular control of corpus luteum formation, function, and regression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18377604" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Autoimmune progesterone dermatitis. Case report with histologic overlap of erythema multiforme and urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5761807" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Auto-immune progesterone eczema. An endogenous progesterone hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18222339" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Autoimmune progesterone dermatitis associated with infertility treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28483311" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Progestogen Hypersensitivity: Heterogeneous Manifestations with a Common Trigger.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7829735" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Autoimmune progesterone dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24565633" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Iatrogenic autoimmune progesterone dermatitis treated with a novel intramuscular progesterone desensitization protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21092951" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Autoimmune progesterone dermatitis: clinical presentation and management with progesterone desensitization for successful in vitro fertilization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15287986" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Autoimmune progesterone dermatitis in a patient with endometriosis: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15341029" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Chronic idiopathic urticaria exacerbated with progesterone therapy treated with novel desensitization protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4398434" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Autoimmune progesterone urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11075293" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Autoimmune progesterone urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15115523" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Autoimmune progesterone dermatitis presenting with purpura and petechiae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27032848" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Autoimmune progesterone dermatitis: Case report with history of urticaria, petechiae and palpable pinpoint purpura triggered by medical abortion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24750448" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Autoimmune progesterone dermatitis that changed its clinical manifestation from anaphylaxis to fixed drug eruption-like erythema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19958448" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Case of autoimmune progesterone dermatitis presenting as fixed drug eruption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16891434" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Chronic vulvovaginal pruritus treated successfully with GnRH analogue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5822339" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Progesterone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9619670" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Autoimmune progesterone dermatitis and stomatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3989808" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Progesterone-induced erythema multiforme.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19691230" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Autoimmune progesterone dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28885418" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Autoimmune Progesterone Dermatitis Presenting as Stevens-Johnson Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29528935" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Autoimmune Progesterone Dermatitis Mistaken for Stevens-Johnson Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12775127" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Autoimmune progesterone dermatitis and its manifestation as anaphylaxis: a case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6149462" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Progesterone sensitivity as a cause of recurrent anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21417747" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A case of progesterone-induced anaphylaxis, cyclic urticaria/angioedema, and autoimmune dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28258855" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Anaphylaxis due to progesterone hypersensitivity successfully treated with omalizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2137160" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Autoimmune progesterone dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3403867" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The treatment of glucocorticosteroid-dependent chronic urticaria with stanozolol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20500158" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Autoimmune progesterone dermatitis: treatment with oophorectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21564176" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Autoimmune progesterone dermatitis: a diagnosis easily missed.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12140482" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Autoimmune progesterone dermatitis manifested as erythema annulare centrifugum: Confirmation of progesterone sensitivity by in vitro interferon-gamma release.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27489085" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Autoimmune progesterone dermatitis: Case report of an unexpected treatment reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31217816" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Autoimmune progesterone dermatitis following vaginal progesterone exposure in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16522535" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Autoimmune progesterone dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7344688" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Autoimmune progesterone dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4351124" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Autoimmune progesterone dermatitis of pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2568048" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Two cases of autoimmune progesterone dermatitis. Immunohistochemical and serological studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22723800" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Role of female sex hormones, estradiol and progesterone, in mast cell behavior.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17084457" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Estradiol activates mast cells via a non-genomic estrogen receptor-alpha and calcium influx.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2442235" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Effects of sex hormones on basophil histamine release in recurrent idiopathic anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19289782" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Autoimmune progesterone dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1505180" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Corticosteroid or steroid allergy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7096543" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Identification of a 17-hydroxyprogesterone-binding immunoglobulin in the serum of a woman with periodic rashes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9258316" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Autoimmune progesterone dermatitis: onset in a women without previous exogenous progesterone exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21252802" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Progesterone autoimmune dermatitis with positive autologous serum skin test result.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23816482" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Skin test reactivity to female sex hormones in women with primary unexplained recurrent pregnancy loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18869257" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Skin tests with endocrine substances; method of Zondek and Bromberg.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30953782" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Development of a progesterone-specific IgE assay for diagnosing patients with suspected progestogen hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30468931" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Cyclical hypersensitivity, anaphylaxis, and related hormonal reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21284652" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A case report of breastfeeding anaphylaxis: successful prophylaxis with oral antihistamines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19622944" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Recurrent postpartum anaphylaxis with breast-feeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1682680" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Breastfeeding anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25683236" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The menstrual cycle and the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31909158" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Catamenial dermatoses associated with autoimmune, inflammatory, and systemic diseases: A systematic review,.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7822514" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Estrogen dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9076430" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Estrogen dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3214953" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : A premenstrual urticarial eruption treated with bilateral oophorectomy and hysterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15967937" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Estrogen dermatitis: treatment with progestin-only pill.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16043907" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Estrogen dermatitis responding to leuprolide acetate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23886228" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Heterogeneity in presentation and treatment of catamenial anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24811034" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Catamenial anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1987869" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Cyclic anaphylaxis associated with menstruation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24779868" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Catamenial dermatoses: has anyone ever considered prostaglandins?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1115176" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Levels of prostaglandins F-2alpha and E-2 in human endometrium during the menstrual cycle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8297847" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Distribution of mast cells and the effect of their mediators on contractility in human myometrium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17375739" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A case of breastfeeding anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9352418" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Autoimmune progesterone dermatitis: effective prophylactic treatment with danazol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24766875" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : The diagnosis and management of acute and chronic urticaria: 2014 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18502492" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19910036" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26895621" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8305302" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Progesterone-induced urticaria: response to buserelin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3306508" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Recurrent anaphylaxis in menstruating women: treatment with a luteinizing hormone-releasing hormone agonist--a preliminary report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12537774" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10065775" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9464714" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11978277" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9767301" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Autoimmune progesterone dermatitis: treatment with oophorectomy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
